Can-Fite BioPharma Full Year 2023 Earnings: Revenues Disappoint

Can-Fite BioPharma (TLV:CANF) Full Year 2023 Results

Key Financial Results

• Net loss: US$7.63m (loss narrowed by 25% from FY 2022).
• US$0.006 loss per share (improved from US$0.012 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Can-Fite BioPharma Revenues Disappoint

Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) was mostly in line with analyst estimates.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 5 warning signs for Can-Fite BioPharma (2 are concerning!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.